RecruitingNCT06475898
Longitudinal Endpoint Assessment of Disease Burden in HD
Sponsor
Huntington Study Group
Enrollment
600 participants
Start Date
Jun 25, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with huntington disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06475898
Related Trials
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
NCT073786448 locations
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT0732670920 locations
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
NCT0666741445 locations
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
NCT068266125 locations
Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease
NCT075138441 location